Novo Nordisk

Back to home


Turoctocog Alfa
 


Zero Incidence Of Factor Viii Inhibitors And Successful Haemostatic Response In Previously Factor Viii-Treated Haemophilia A Patients Switching To Turoctocog Alfa In A Non-Interventional Study

Authors
Escuriola-Ettingshausen C et al.


© 2020 Novo Nordisk A/S Data privacy Cookie Policy